Quick Answer
Olema Pharmaceuticals, Inc. reported Net Income Loss of -$162.45 million for the year ending 2025.
- Olema Pharmaceuticals, Inc. showed a decrease of -25.5% in Net Income Loss from 2024 to 2025.
- This data is from Olema Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.69 million | Q2 2020: -$2.45 million | Q3 2020: -$7.84 million | Q1 2021: -$15.34 million | Q2 2021: -$16.41 million | Q3 2021: -$17.71 million | Q1 2022: -$23.03 million | Q2 2022: -$32.86 million | Q3 2022: -$22.72 million | Q1 2023: -$28.29 million | Q2 2023: -$20.10 million | Q3 2023: -$21.50 million | Q1 2024: -$30.97 million | Q2 2024: -$30.38 million | Q3 2024: -$34.56 million | Q1 2025: -$30.39 million | Q2 2025: -$43.78 million | Q3 2025: -$42.22 million.
- Over the full 7 years of available data (2019 to 2025), Olema Pharmaceuticals, Inc.'s Net Income Loss has declined by 3,663.9%.
- Historical annual values: Fiscal year 2025: -$162.45 million | Fiscal year 2024: -$129.47 million | Fiscal year 2023: -$96.66 million | Fiscal year 2022: -$104.79 million | Fiscal year 2021: -$71.10 million | Fiscal year 2020: -$22.12 million | Fiscal year 2019: -$4.32 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: